^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) + Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
For pediatric and AYA patients with Ph-negative or Ph-like ALL experiencing early or late first relapse, the panel recommends initial treatment with systemic therapy....If patients experience CR2 and are MRD positive...blinatumomab, tisagenlecleucel and inotuzumab ozogamicin may be considered.
